[Skip to Navigation]
Views 823
Citations 0
Invited Commentary
November 25, 2020

Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer: Is Rising Utilization Justified by Evidence?

Author Affiliations
  • 1Department of Urology, University of Washington, Seattle, Washington
  • 2Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington
JAMA Oncol. 2021;7(1):59-60. doi:10.1001/jamaoncol.2020.6045

A diagnosis of localized prostate cancer poses an array of treatment decisions for patients and treating physicians. Prostate cancer is notable for the remarkable diversity in clinical outcomes that range from an indolent course, with no impact on the patient if left untreated, to rapid progression to metastatic disease and cancer-specific death. Consequently, treatment options also span conservative approaches, such as active surveillance to radical curative therapy that involves prostatectomy or radiotherapy. Unfortunately, these interventions have adverse effects that can substantially affect quality of life. Thus, a major objective involves stratifying patients based on individual risk for aggressive disease behavior and basing treatment recommendations accordingly. Traditionally, risk stratification uses readily available clinical parameters that include the level of serum prostate-specific antigen, clinical stage, and the histological Gleason grade assessed from prostate biopsy. While clearly useful as guidelines for estimating risks of populations, the resulting classifications of low, intermediate, and high risk, as well as subdivisions within them, are far from perfect in determining what the precise trajectory will be for an individual patient.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words